13F-HR filed by Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 19 holding rows worth $1,305,660,829.
- Accession
- 0001193125-26-054833
- Filer
- CIK 1703031
- Filed
- 2026-02-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 19 entries on the cover page, a total value of $1,305,660,829 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,305,660,830 with VALUE read as dollars as filed, 13F file number 028-18477. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerBain Capital Life Sciences Investors II, LLC 028-20816
- included managerBain Capital Life Sciences Fund II, L.P. 028-20814
- included managerBCLS II Investco (GP), LLC 028-22976
- included managerBCLS II Investco, LP 028-22978
- included managerBain Capital Life Sciences III General Partner, LLC 028-22975
- included managerBain Capital Life Sciences Fund III, L.P. 028-22979
- included managerBain Capital Life Sciences Opportunities III GP, LLC 028-22968
- included managerBain Capital Life Sciences Opportunities III, LP 028-22966
- included managerBCLS Fund III Investments GP, LLC 028-25138
- included managerBCLS Fund III Investments, LP 028-25140
- included managerBain Capital Life Sciences IV General Partner, LLC
- included managerBain Capital Life Sciences Fund IV, L.P.
- included managerBain Capital Life Sciences Opportunities IV GP, LLC
- included managerBain Capital Life Sciences Opportunities IV, L.P.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| HEARTFLOW INC | 42238D107 | COM | 12,448,158 | $362,863,806 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 7,306,566 | $256,314,335 | dollars as filed | |
| OLEMA PHARMACEUTICALS INC | 68062P106 | COM | 8,508,641 | $212,716,025 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 17,600,621 | $106,131,745 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 2,802,081 | $77,757,748 | dollars as filed | |
| SOLID BIOSCIENCES INC | 83422E204 | COMMON STOCK | 7,911,669 | $44,621,813 | dollars as filed | |
| UPSTREAM BIO INC | 91678A107 | COMMON STOCK | 1,329,544 | $36,097,120 | dollars as filed | |
| X4 PHARMACEUTICALS INC | 98420X202 | COMMON STOCK | 7,967,454 | $31,869,816 | dollars as filed | |
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 743,592 | $30,643,426 | dollars as filed | |
| KYVERNA THERAPEUTICS INC | 501976104 | COMMON STOCK | 3,110,000 | $29,234,000 | dollars as filed | |
| ANNEXON INC | 03589W102 | COM | 5,249,069 | $26,350,326 | dollars as filed | |
| RAPID MICRO BIOSYSTEMS INC | 75340L104 | CLASS A COM | 8,434,560 | $24,460,224 | dollars as filed | |
| CABALETTA BIO INC | 12674W109 | COMMON STOCK | 9,677,125 | $21,192,904 | dollars as filed | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 7,171,910 | $13,698,348 | dollars as filed | |
| MERSANA THERAPEUTICS INC | 59045L205 | COM | 346,545 | $10,025,547 | dollars as filed | |
| ATEA PHARMACEUTICALS INC | 04683R106 | COMMON STOCK | 2,485,638 | $8,873,728 | dollars as filed | |
| TANGO THERAPEUTICS INC | 87583X109 | COM | 653,493 | $5,789,948 | dollars as filed | |
| Xilio Therapeutics Inc. | 98422T100 | COM | 7,372,686 | $4,719,994 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV-27 | N62509117 | WTS | 99,999 | $2,299,977 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001193125-26-054833 | this filing | 2026-02-17 | acceptance time not in the bulk data set |